Literature DB >> 12180533

Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers.

Vimon Tantishaiyakul1, Kamonthip Wiwattanawongsa, Sirirat Pinsuwan, Srirat Kasiwong, Narubodee Phadoongsombut, Sanae Kaewnopparat, Nattha Kaewnopparat, Yon Rojanasakul.   

Abstract

PURPOSE: Prodrug of non-steroidal anti-inflammatory drugs (NSAIDs) or NSAIDs linked with guaiacol have been reported to suppress gastrointestinal (GI) toxicity or induce GI protective effect. In this study. mefenamic-guaiacol ester was synthesized and its physicochemical properties. stability, and transport across Caco-2 monolayers were investigated.
METHODS: Synthesis of the ester was carried out using mefenamic acid, guaiacol. N. N'-dimethylaminopyridine, and N,N'dicyclohexylcarbodiimide. The hydrolysis of the ester was investigated in aqueous buffer solutions pH 1-12 as well as in Caco-2 homogenate, human plasma, and porcine liver esterase. Caco-2 cell monolayers were utilized for transport studies. Due to the high lipophilicity of the ester with a calculated logP of 6.15, bovine serum albumin (BSA, 4%) was included in the receiver compartment to obtain a good in vitro-in vivo correlation. Permeation of the ester was assessed with or without the exposure of cells to PMSF, an inhibitor of esterase.
RESULTS: The ester was stable at a wide pH range from 1-10. However, it was hydrolyzed by enzymes from porcine liver esterase and Caco-2 homogenate. With the PMSF exposure on the apical (AP) side and in the presence of 4% BSA on the basolateral (BL) side, the transported amount of the ester from AP-to-BL direction was 14.63% after 3 hr with a lag time of 23 min. The Papp for the ester was 4.72 x 10(-6) cm s(-1).
CONCLUSION: The results from hydrolysis studies indicate that this ester is a prodrug. The Papp value suggests the moderate absorption characteristic of the compound. The accumulation of this highly lipophilic ester in Caco-2 cells is reduced in the presence of BSA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180533     DOI: 10.1023/a:1016470523923

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Transport of cosalane-a highly lipophilic novel anti-HIV agent-across caco-2 cell monolayers.

Authors:  D Pal; C Udata; A K Mitra
Journal:  J Pharm Sci       Date:  2000-06       Impact factor: 3.534

2.  Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds.

Authors:  M Yazdanian; S L Glynn; J L Wright; A Hawi
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

3.  Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2.

Authors:  G Krishna; K Chen; C Lin; A A Nomeir
Journal:  Int J Pharm       Date:  2001-07-03       Impact factor: 5.875

Review 4.  Antiinflammatory drugs and gastric mucosal damage.

Authors:  E L Semble; W C Wu
Journal:  Semin Arthritis Rheum       Date:  1987-05       Impact factor: 5.532

5.  In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth.

Authors:  S Yee
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  High lipophilicity decreases drug transport across intestinal epithelial cells.

Authors:  P Wils; A Warnery; V Phung-Ba; S Legrain; D Scherman
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

7.  Methoxybutropate microencapsulation by gelatin-acacia complex coacervation.

Authors:  G F Palmieri; D Lauri; S Martelli; P Wehrle
Journal:  Drug Dev Ind Pharm       Date:  1999-04       Impact factor: 3.225

8.  Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.

Authors:  M Brunner-Guenat; P A Carrupt; G Lisa; B Testa; S Rose; K Thomas; P Jenner; P Ventura
Journal:  J Pharm Pharmacol       Date:  1995-10       Impact factor: 3.765

9.  Studies on the gastric tolerability of the new non-steroidal anti-inflammatory drug amtolmetin guacyl.

Authors:  E Tubaro; L Belogi; C M Mezzadri; L Ruco; A Stopacciaro
Journal:  Arzneimittelforschung       Date:  1995-12

10.  Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation.

Authors:  V K Tammara; M M Narurkar; A M Crider; M A Khan
Journal:  J Pharm Sci       Date:  1994-05       Impact factor: 3.534

View more
  4 in total

1.  Experimental and computational studies of epithelial transport of mefenamic acid ester prodrugs.

Authors:  Kamonthip Wiwattanawongsa; Vimon Tantishaiyakul; Luelak Lomlim; Yon Rojanasakul; Sirirat Pinsuwan; Sanae Keawnopparat
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

2.  Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT.

Authors:  Xiaowan Zheng; James E Polli
Journal:  Int J Pharm       Date:  2010-07-01       Impact factor: 5.875

3.  Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.

Authors:  Amit Kokate; Xiaoling Li; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2006-12-05       Impact factor: 3.651

Review 4.  Prodrugs of NSAIDs: A Review.

Authors:  Kamal Shah; Jeetendra K Gupta; Nagendra S Chauhan; Neeraj Upmanyu; Sushant K Shrivastava; Pradeep Mishra
Journal:  Open Med Chem J       Date:  2017-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.